-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Telix Pharmaceuticals with Outperform Rating, Announces Price Target of $22

Benzinga·06/05/2025 11:57:22
Listen to the news
Wedbush analyst David Nierengarten initiates coverage on Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform rating and announces Price Target of $22.